Ixekizumab: targeting plaque psoriasis and psoriatic arthritis
Sign Up to like & getrecommendations! Published in 2019 at "Prescriber"
DOI: 10.1002/psb.1743
Abstract: Ixekizumab (Taltz) is an anti‐interleukin‐17A monoclonal antibody therapy for the treatment of adults with plaque psoriasis or psoriatic arthritis. This article discusses its efficacy and place in therapy. read more here.
Keywords: psoriatic arthritis; psoriasis psoriatic; ixekizumab; plaque psoriasis ... See more keywords
Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3)
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Dermatological Treatment"
DOI: 10.1080/09546634.2016.1249820
Abstract: Abstract Background: Scalp is a frequently affected and difficult-to-treat area in psoriasis patients. Objective: We assessed the efficacy of ixekizumab in the treatment of patients with scalp psoriasis over 60 weeks using the Psoriasis Scalp… read more here.
Keywords: ixekizumab; treatment; severe psoriasis; psoriasis ... See more keywords
Ixekizumab for the treatment of psoriasis: an update on new data since first approval
Sign Up to like & getrecommendations! Published in 2018 at "Expert Review of Clinical Immunology"
DOI: 10.1080/1744666x.2019.1559730
Abstract: ABSTRACT Introduction: Psoriasis is a chronic immune-mediated skin disease with a multifactorial etiology. Studies have shown that the inflammatory cytokine interleukin-17A (IL-17A) is a key mediator in the pathogenesis. Targeted biologics have changed the outcome… read more here.
Keywords: ixekizumab; treatment; safety; efficacy ... See more keywords
Successful treatment with ixekizumab in a guselkumab‐resistant psoriasis patient
Sign Up to like & getrecommendations! Published in 2020 at "Dermatologic Therapy"
DOI: 10.1111/dth.14585
Abstract: Dear Editor Biologics are revolutionary therapies for psoriasis. Different classes of biologics may be required due to the inefficacy in clinical practice. To date, no studies have assessed the switch between two newer biologics, guselkumab… read more here.
Keywords: guselkumab resistant; ixekizumab; response; treatment ... See more keywords
Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry
Sign Up to like & getrecommendations! Published in 2021 at "Dermatologic Therapy"
DOI: 10.1111/dth.14808
Abstract: To compare drug survival of ixekizumab to other IL‐17 inhibitors (IL‐17i) and TNF inhibitors (TNFi) among patients with psoriasis (PsO) in a real‐world setting. Participants included adult PsO patients enrolled in the Corrona Psoriasis Registry… read more here.
Keywords: drug; drug survival; ixekizumab; real world ... See more keywords
Real life long‐term efficacy and safety of ixekizumab in moderate‐to‐severe psoriasis: A 192 weeks multicentric retrospective study—IL PSO (Italian landscape psoriasis)
Sign Up to like & getrecommendations! Published in 2022 at "Dermatologic Therapy"
DOI: 10.1111/dth.15608
Abstract: Psoriasis is one of the commonest inflammatory skin diseases determining a very high impact on patients' quality of life and daily activities and relationships. Several biologic therapies have been approved through the years for the… read more here.
Keywords: efficacy safety; psoriasis; moderate severe; ixekizumab ... See more keywords
Immediate hypersensitivity reaction to ixekizumab in a patient with psoriasis
Sign Up to like & getrecommendations! Published in 2020 at "Journal of the European Academy of Dermatology and Venereology"
DOI: 10.1111/jdv.16748
Abstract: IXEKIZUMAB is a humanized immunoglobulin G monoclonal antibody targeting the IL 17A, and labelled to treat moderate to severe plaque psoriasis. Benign skin reactions are a common adverse event when using IXEKIZUMAB. In a meta-analysis… read more here.
Keywords: psoriasis; ixekizumab; immediate hypersensitivity; hypersensitivity reaction ... See more keywords
Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure
Sign Up to like & getrecommendations! Published in 2022 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2021-222027
Abstract: Objectives Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin 17A (IL-17A), has shown significant efficacy in the treatment of psoriatic arthritis (PsA) and sustained long-term clinical response without unexpected new safety outcome for an… read more here.
Keywords: safety; psoriatic arthritis; patient years; four clinical ... See more keywords
Ixekizumab: A Review of Its Use for the Management of Moderate to Severe Plaque Psoriasis
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Pharmacotherapy"
DOI: 10.1177/1060028018799982
Abstract: Objective: To review the efficacy, safety, and place in therapy of ixekizumab for the treatment of moderate to severe plaque psoriasis. Data Sources: PubMed (1966 to July 2018) and clinicaltrials.gov were searched using the terms… read more here.
Keywords: ixekizumab; severe plaque; psoriasis; plaque psoriasis ... See more keywords
Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab
Sign Up to like & getrecommendations! Published in 2017 at "Therapeutics and Clinical Risk Management"
DOI: 10.2147/tcrm.s111107
Abstract: Developments in the understanding of the immunopathogenesis of psoriasis have identified interleukin (IL)-17 as the key proinflammatory cytokine in the pathogenesis of plaque psoriasis, with the consequent development of drugs that target this cytokine or… read more here.
Keywords: ixekizumab; clinical efficacy; role; psoriasis ... See more keywords